Significant acquisition of businesses (Details 4)

Jun. 24, 2026

USD ($)

May 28, 2026

USD ($)

Oct. 28, 2025

USD ($)

Sep. 16, 2025

USD ($)

Jun. 25, 2025

USD ($)

Jun. 24, 2025

USD ($)

Apr. 03, 2025

USD ($)

Jun. 30, 2026

USD ($)

Dec. 31, 2025

USD ($)

Sep. 29, 2025

USD ($)

Jul. 11, 2025

USD ($)

Jun. 30, 2025

USD ($)

May 27, 2025

USD ($)

Amounts recognised as of acquisition date for each major class of assets acquired and liabilities assumed [line items]

Cash and cash equivalents recognised as of acquisition date through acquisitions applying the optional concentration test

$ 300,000,000

Cash acquired recognized as of acquisition date through acquisitions applying the optional concentration test

$ 0.0

Regulus Therapeutics Inc.

Amounts recognised as of acquisition date for each major class of assets acquired and liabilities assumed [line items]

Cash offer per outstanding share for acquisitions applying the optional concentration test

$ 7.00

Contingent value right per share for acquisitions applying the optional concentration test

$ 7.00

Portion of consideration paid consisting of cash and cash equivalents for acquisitions applying the optional concentration test

$ 800,000,000

$ 700,000,000

Number of contingent value per share issued for acquisitions applying the optional concentration test

$ 100,000,000

Contingent value right amount for acquisitions applying the optional concentration test

900,000,000

Cash and cash equivalents recognised as of acquisition date through acquisitions applying the optional concentration test

23,000,000

Anthos Therapeutics Inc.

Amounts recognised as of acquisition date for each major class of assets acquired and liabilities assumed [line items]

Portion of consideration paid consisting of cash and cash equivalents for acquisitions applying the optional concentration test

$ 900,000,000

Potential milestone maximum payment for acquisitions applying the optional concentration test

2,100,000,000

Cash and cash equivalents recognised as of acquisition date through acquisitions applying the optional concentration test

47,000,000

Tourmaline Bio, Inc.

Amounts recognised as of acquisition date for each major class of assets acquired and liabilities assumed [line items]

Cash offer per outstanding share for acquisitions applying the optional concentration test

$ 48.00

Portion of consideration paid consisting of cash and cash equivalents for acquisitions applying the optional concentration test

$ 1,400,000,000

Cash and cash equivalents recognised as of acquisition date through acquisitions applying the optional concentration test

200,000,000

Private clinical-stage biotech company

Amounts recognised as of acquisition date for each major class of assets acquired and liabilities assumed [line items]

Portion of consideration paid consisting of cash and cash equivalents for acquisitions applying the optional concentration test

$ 400,000,000

Cash and cash equivalents recognised as of acquisition date through acquisitions applying the optional concentration test

18,000,000

Non-controlling interests for acquisitions applying the optional concentration test

400,000,000

Excellergy, Inc.

Amounts recognised as of acquisition date for each major class of assets acquired and liabilities assumed [line items]

Portion of consideration paid consisting of cash and cash equivalents for acquisitions applying the optional concentration test

$ 900,000,000

Potential milestone maximum payment for acquisitions applying the optional concentration test

1,100,000,000

Pikavation Therapeutics, Inc.

Amounts recognised as of acquisition date for each major class of assets acquired and liabilities assumed [line items]

Portion of consideration paid consisting of cash and cash equivalents for acquisitions applying the optional concentration test

$ 1,800,000,000

Potential milestone maximum payment for acquisitions applying the optional concentration test

1,200,000,000

Acquired research and development intangible assets recognised as of acquisition date | Regulus Therapeutics Inc.

Amounts recognised as of acquisition date for each major class of assets acquired and liabilities assumed [line items]

Intangible assets other than goodwill for acquisitions applying the optional concentration test

$ 800,000,000

Acquired research and development intangible assets recognised as of acquisition date | Anthos Therapeutics Inc.

Amounts recognised as of acquisition date for each major class of assets acquired and liabilities assumed [line items]

Intangible assets other than goodwill for acquisitions applying the optional concentration test

$ 900,000,000

Acquired research and development intangible assets recognised as of acquisition date | Tourmaline Bio, Inc.

Amounts recognised as of acquisition date for each major class of assets acquired and liabilities assumed [line items]

Intangible assets other than goodwill for acquisitions applying the optional concentration test

$ 1,200,000,000

Acquired research and development intangible assets recognised as of acquisition date | Private clinical-stage biotech company

Amounts recognised as of acquisition date for each major class of assets acquired and liabilities assumed [line items]

Intangible assets other than goodwill for acquisitions applying the optional concentration test

$ 400,000,000

Acquired research and development intangible assets recognised as of acquisition date | Excellergy, Inc.

Amounts recognised as of acquisition date for each major class of assets acquired and liabilities assumed [line items]

Intangible assets other than goodwill for acquisitions applying the optional concentration test

900,000,000

Acquired research and development intangible assets recognised as of acquisition date | Pikavation Therapeutics, Inc.

Amounts recognised as of acquisition date for each major class of assets acquired and liabilities assumed [line items]

Intangible assets other than goodwill for acquisitions applying the optional concentration test

$ 1,800,000,000

Cash and cash equivalents recognised as of acquisition date

Amounts recognised as of acquisition date for each major class of assets acquired and liabilities assumed [line items]

Cash and cash equivalents recognised as of acquisition date through acquisitions applying the optional concentration test

$ 70,000,000

Cash acquired

Amounts recognised as of acquisition date for each major class of assets acquired and liabilities assumed [line items]

Cash acquired recognized as of acquisition date through acquisitions applying the optional concentration test

$ 5,000,000

Cash acquired | Excellergy, Inc.

Amounts recognised as of acquisition date for each major class of assets acquired and liabilities assumed [line items]

Cash acquired recognized as of acquisition date through acquisitions applying the optional concentration test

$ 5,000,000